Are adults in beijing still protected against tetanus? a study investigates
NCT ID NCT07724379
First seen Jul 24, 2026 · Last updated Jul 24, 2026
Summary
This observational study aims to measure tetanus antibody levels in healthy adults living in Beijing, China. Researchers will analyze how antibody protection varies across different age groups and whether vaccination history predicts current immunity. Participants provide a single blood sample and answer questions about past tetanus shots. The study does not involve any treatment or intervention.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help identify gaps in tetanus immunity among adults and guide future vaccination strategies.
- What could go wrong
- This is an observational study, not a trial of a new treatment. It only measures antibody levels and does not test any intervention.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TETANUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new vaccine shield older kids and adults from three deadly infections?
- Can a Five-Part vaccine bolster protection against three serious infections?
- Can a single shot keep tetanus at bay?
- Will a single DTP vaccine dose protect for a decade? study tracks antibodies
- Can a new tetanus shot offer stronger protection?
- New tetanus antibody could replace Blood-Derived treatments